Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study

Louis E. Schroder, Danika Lew, Robert C. Flanigan, Mario A. Eisenberger, Thomas E. Seay, Neel Hammond, Burton M. Needles, E. David Crawford

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.

Original languageEnglish (US)
Pages (from-to)145-148
Number of pages4
JournalUrologic oncology
Volume6
Issue number4
DOIs
StatePublished - Jul 3 2001

Keywords

  • Renal carcinoma
  • Suramin

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this